Table 3.

Attrition-weighted adjusted incidence rate ratios for benzodiazepine and anticholinergic medication use and incident dementia, stratified by cognition, sex and age

	Incidence rate ratio (95% confidence interval) by exposure
Subgroup	Any Benzodiazepines	Any ACB3	Any ACB12
MMSE at Y2 > 25	0.72 (0.35,1.50)	2.28 (1.32,3.92)*	0.99 (0.68,1.43)
MMSE at Y2 ≤ 25	1.23 (0.74,2.06)	0.94 (0.51,1.73)	0.78 (0.54,1.12)
Male	0.29 (0.06,1.31)	2.06 (0.78,5.46)	1.11 (0.66,1.89)
Female	1.17 (0.77,1.78)	1.24 (0.77,2.01)	0.85 (0.63,1.16)
Younger (born 1920–1929)	1.31 (0.52,3.27)	1.16 (0.45,3.01)	1.57 (0.82,3.00)
Older (born before 1920)	1.06 (0.69,1.61)	1.27 (0.78,2.09)	0.77 (0.58,1.03)

*p < 0.01

Abbreviations: MMSE Mini-Mental State Examination, ACB Anticholinergic Cognitive Burden, ACB12 use of a medicine with an ACB score of 1 or 2. Scores correspond to possibly anticholinergic (score 1), probably anticholinergic (score 2) and definitely anticholinergic (score 3). Number of observations and adjusted percentage in each group are reported in Additional file 3